Literature DB >> 2369974

Depletion in choline containing phospholipids of LpB particles in adequately controlled type I insulin-dependent diabetes mellitus.

C Fievet1, O Ziegler, H J Parra, L Mejean, J C Fruchart, P Drouin.   

Abstract

The aim of the present study was to evaluate the serum and lipoprotein levels of choline--containing phospholipids (lecithin, lysolecithin and sphingomyelin) in a group of type I diabetic patients in fair metabolic control. Forty-eight male adult diabetic patients without macroproteinuria were compared with 48 healthy controls matched for age and body weight. Total cholesterol and phospholipids were assessed in plasma and in apolipoprotein B (apoB) and non apoB containing lipoprotein particles (Lp B and Lp non B particles) separated using precipitation with Concanavalin A. When compared to the control group, diabetic patients have significantly lower serum phospholipids and phospholipids and cholesterol content of LpB particles. All the other parameters studied were similar in the two groups. The phospholipids/cholesterol ratio, calculated in LpB particles is also significantly reduced in the diabetic group. These results strongly suggest a depletion in the choline containing phospholipid content of LpB particles and therefore an alteration of the surface components of atherogenic particles in type I diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369974

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  2 in total

1.  Perturbations in the lipid profile of individuals with newly diagnosed type 1 diabetes mellitus: lipidomics analysis of a Diabetes Antibody Standardization Program sample subset.

Authors:  Christina M Sorensen; Jie Ding; Qibin Zhang; Thierry Alquier; Rui Zhao; Patricia W Mueller; Richard D Smith; Thomas O Metz
Journal:  Clin Biochem       Date:  2010-05-16       Impact factor: 3.281

Review 2.  Functional Lipids in Autoimmune Inflammatory Diseases.

Authors:  Michele Dei Cas; Gabriella Roda; Feng Li; Francesco Secundo
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.